Strategic merger Kapadi combines OncoBay Clinical with Clinscience and Exom Group, creating a unified global provider for technology- and data-driven oncology trials; potential cross-sell opportunities across broader capabilities and geographies.

Immuno-oncology focus Specialization in immuno-oncology and cell therapy with end-to-end control and integrated cell manufacturing suggests opportunities to support complex, high-value oncology programs requiring specialized CRO services.

Global trials access Boutique CRO with a streamlined tech framework and a trained site network can serve pharma and biotech firms looking for agile execution and rapid site activation across multiple regions.

Strategic partnerships Historical collaborations with Lymphoma Society, Hillstream Biopharma, Chimeric Therapeutics, Protocol First, and Moffitt signal credibility; leverage established relationships to access new oncology clients seeking specialized partners.

Growth signals Revenue range and mid-size employee base indicate scalable operations poised for expansion post-merger; identify opportunities to upsell comprehensive data science, regulatory support, and advanced manufacturing services to existing and new clients.